The objectives of this study were to evaluate the safety and anti-inflammatory and wound-healing characteristics of carbohydrate-derived fulvic acid (CHD-FA) in rats. CHD-FA (=100 mg/kg p.o.) effectively reduced carrageenan-induced paw edema in rats, which was comparable to 10 mg/kg p.o. indomethacin. Topical application of CHD-FA, formulated to contain 1.75% active product in a cetomicrogol cream at pH 1.98, compared favorably with fusidic acid cream (10 mg/g) in accelerating the healing of excised wounds infected with Staphylococcus aureus. No signs of toxicity were observed in rats during the 6-day acute and 6-month chronic treatment with CHD-FA (100 mg/kg p.o.). Topical application of CHD-FA, formulated in UEA cream and applied to the right ears of mice at 400 mg/g body weight on days 1 and 738, produced no adverse events. No signs of toxicity were observed in the teratogenicity study, in which CHD-FA was administered at 100 mg/kg p.o. to pregnant female mice 3 days before fertilization to 14 days of pregnancy. In conclusion, CHD-FA is a safe compound with anti-inflammatory and wound-healing properties and merits further evaluation in the treatment of patients suffering from similar conditions. Drug Dev Res 73: 1823, 2012. (c) 2011 Wiley Periodicals, Inc.